Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EPS (Basic): 2020-2025

Historic EPS (Basic) for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $1.71.

  • Apellis Pharmaceuticals' EPS (Basic) rose 471.74% to $1.71 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.35, marking a year-over-year increase of 117.33%. This contributed to the annual value of -$1.60 for FY2024, which is 64.04% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' EPS (Basic) stood at $1.71, which was up 618.18% from -$0.33 recorded in Q2 2025.
  • Apellis Pharmaceuticals' EPS (Basic)'s 5-year high stood at $1.71 during Q3 2025, with a 5-year trough of -$2.72 in Q2 2021.
  • In the last 3 years, Apellis Pharmaceuticals' EPS (Basic) had a median value of -$0.54 in 2024 and averaged -$0.49.
  • Its EPS (Basic) has fluctuated over the past 5 years, first crashed by 248.54% in 2021, then skyrocketed by 471.74% in 2025.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' EPS (Basic) stood at -$1.53 in 2021, then increased by 1.96% to -$1.50 in 2022, then spiked by 52.00% to -$0.72 in 2023, then skyrocketed by 59.72% to -$0.29 in 2024, then soared by 471.74% to $1.71 in 2025.
  • Its EPS (Basic) stands at $1.71 for Q3 2025, versus -$0.33 for Q2 2025 and -$0.74 for Q1 2025.